세계의 비침습적 간 모니터 시장 : 검사 유형, 기술, 용도, 최종사용자, 환자 유형, 대상 질환별 - 예측(2025-2030년)

The Non-Invasive Liver Monitor Market was valued at USD 8.04 billion in 2024 and is projected to grow to USD 8.57 billion in 2025, with a CAGR of 6.98%, reaching USD 12.05 billion by 2030.

The non-invasive liver monitor market has witnessed significant evolution in response to rising demand for safer and more patient-friendly diagnostic solutions. In recent years, there has been a pronounced shift away from traditional invasive methods, driven by the increasing clinical need to reduce patient discomfort, minimize recovery time, and lower the risk of complications. Advancements in technology, tighter regulatory guidelines, and heightened awareness among healthcare providers have collectively spurred the adoption of non-invasive techniques. The landscape today presents a confluence of innovative imaging and biomarker-based tools that are reshaping liver disease diagnosis and management. This market overview provides an in-depth look at the emerging trends and the strategic drivers behind the growth of these non-invasive modalities. With an emphasis on reliability, accuracy, and real-time monitoring capabilities, this executive summary lays the foundation for understanding the transformative impact these technologies are having on both clinical practice and patient outcomes. It is an invitation to explore the data-driven insights and comprehensive research that underpin the trends steering the market's current and future direction.

Transformative Market Shifts Shaping the Non-Invasive Liver Monitor Landscape

The non-invasive liver monitor sector is experiencing transformative shifts that are redefining traditional paradigms in medical diagnostics. The convergence of robust technological advancements with innovative clinical applications has reshaped how healthcare providers evaluate liver conditions. Breakthroughs in imaging modalities and biomarker detection have not only enhanced diagnostic accuracy but also provided dynamic and quantifiable insights into liver function. Companies and research institutions alike are investing heavily in research and development, resulting in enhanced computational algorithms and more precise measurement techniques. Additionally, changing patient expectations and an increased focus on preventive healthcare have catalyzed the integration of non-invasive monitors in routine screening processes. Payers and healthcare systems are beginning to recognize the long-term economic benefits of early detection, which further fuels market momentum. Regulatory bodies are streamlining approval pathways to accommodate emerging technologies, thereby ensuring broader accessibility and trust. This evolving ecosystem is marked by collaborative efforts among clinicians, engineers, and regulatory experts, heralding a new era where continuous monitoring and minimally invasive assessments drive better clinical outcomes and overall patient well-being.

Key Insights from Comprehensive Market Segmentation

Detailed market segmentation provides an intricate understanding of the non-invasive liver monitor industry, revealing diverse pathways for growth and innovation. The analysis begins by categorizing the tests into blood-based biomarker tests and imaging-based tests, which sets the stage for differentiating diagnostic approaches. Technologies forming the backbone of these methodologies span across Computed Tomography (CT)-Based Techniques, Magnetic Resonance Elastography (MRE), Near-Infrared Spectroscopy (NIRS), Serum Biomarker Panels & Scoring, and Ultrasound Elastography. Further segmentation based on application highlights the critical roles of disease staging and monitoring, early disease diagnosis, and post-surgery monitoring, each serving as a vital node in optimizing patient care. The segmentation extends to the end-user level, examining the dynamics within diagnostic centers, hospitals and clinics, as well as research institutions that drive innovation through real-world application. Patient-specific divisions-ranging from adult, geriatric, to pediatric groups-offer tailored insights that facilitate focus on specific demographic needs. Moreover, the market is segmented by targeted diseases such as cirrhosis, fatty liver disease, hepatitis, and liver fibrosis, with a nuanced exploration of hepatitis further broken down into hepatitis B and hepatitis C. This layered segmentation enables a strategic approach, ensuring that each facet of the market is addressed with precision.

Based on Test Types, market is studied across Blood-Based Biomarker Tests and Imaging-Based Tests.

Based on Technology, market is studied across Computed Tomography (CT)-Based Techniques, Magnetic Resonance Elastography (MRE), Near-Infrared Spectroscopy (NIRS), Serum Biomarker Panels & Scoring, and Ultrasound Elastography.

Based on Application, market is studied across Disease Staging & Monitoring, Early Disease Diagnosis, and Post-Surgery Monitoring.

Based on End-User, market is studied across Diagnostic Centers, Hospitals & Clinics, and Research Institutions.

Based on Patient Type, market is studied across Adult, Geriatric, and Pediatric.

Based on Targeted Diseases, market is studied across Cirrhosis, Fatty Liver Disease, Hepatitis, and Liver Fibrosis. The Hepatitis is further studied across Hepatitis B and Hepatitis C.

Key Regional Insights & Emerging Global Trends

Regional analysis indicates that market maturity and adoption rates vary significantly across global territories. In the Americas, robust healthcare infrastructure coupled with increasing investments in research have catalyzed a rapid assimilation of non-invasive diagnostic techniques. The Europe, Middle East & Africa region, with its diverse regulatory frameworks and varying levels of technological integration, presents a mix of mature and emerging markets where tailored regional strategies are essential. Meanwhile, the Asia-Pacific region stands out due to its expansive patient base, rapid urbanization, and government initiatives aimed at modernizing healthcare services. Each of these regions contributes distinctively to the global market landscape. The Americas continue to lead in terms of technological innovation and funding, Europe and parts of Africa are leveraging collaborative networks and regulatory advancements to boost market penetration, and Asia-Pacific is witnessing significant growth driven by an emphasis on preventive healthcare and scalable clinical applications. Together, these regions paint a dynamic picture of a rapidly evolving global market that is responsive to local needs while remaining interconnected through shared technological trends.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Major Industry Players and Strategic Business Insights

The competitive landscape of the non-invasive liver monitor market is largely defined by a cohort of pioneering companies committed to innovation and excellence. Industry leaders such as Abbott Laboratories, Alpinion Medical Systems USA Inc., and Bruker Corporation GmbH are at the forefront of leveraging advanced technologies to refine diagnostic accuracy. Canon Medical Systems Corporation and Chison Medical Imaging Co., Ltd. have made significant strides in developing cutting-edge imaging systems, while Clarius Mobile Health, Inc. and Echosens S.A. continue to drive transformation through mobile and portable diagnostic devices. Other influential players, including Esaote S.p.A., F. Hoffmann-La Roche AG, and Fujifilm Holdings Corporation, have expanded their portfolio to include integrated solutions that combine biomarker panels with imaging data. GE HealthCare Technologies Inc., Hologic, Inc., and iLiv Diagnostics Inc. are enhancing market reach through robust clinical partnerships and research collaborations. Notably, companies such as Konica Minolta, Inc., Koninklijke Philips N.V., and Mindray Medical International Limited are spearheading efforts to integrate automation and digital analytics into routine diagnostics. Perspectum Diagnostics Ltd., Quibim, Randox Laboratories Ltd., Resonance Health Limited, Resoundant, Inc., Samsung Medison Co., Ltd., Siemens Healthcare Private Limited, Supersonic Imagine S.A., and Wuxi HISKY Medical Technologies Co., Ltd. also play critical roles, collectively enriching the ecosystem with a diverse range of innovative products and strategic insights.

The report delves into recent significant developments in the Non-Invasive Liver Monitor Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alpinion Medical Systems USA Inc., Bruker Corporation GmbH, Canon Medical Systems Corporation, Chison Medical Imaging Co., Ltd., Clarius Mobile Health, Inc., Echosens S.A., Esaote S.p.A., F. Hoffmann-La Roche AG, Fujifilm Holdings Corporation, GE HealthCare Technologies Inc., Hologic, Inc., iLiv Diagnostics Inc., Konica Minolta, Inc., Koninklijke Philips N.V., Mindray Medical International Limited, Perspectum Diagnostics Ltd., Quibim, Randox Laboratories Ltd., Resonance Health Limited, Resoundant, Inc., Samsung Medison Co., Ltd., Siemens Healthcare Private Limited, Supersonic Imagine S.A., and Wuxi HISKY Medical Technologies Co., Ltd.. Actionable Recommendations for Future Industry Leadership

Industry leaders must adopt a multi-faceted strategy to harness the full potential of the non-invasive liver monitor market. First, investing in next-generation technological platforms that integrate both imaging and biomarker data can provide more comprehensive diagnostic insights, thus improving both precision and patient outcomes. Leaders should also prioritize collaborations with academic institutions and regulatory agencies to expedite the validation and clinical acceptance of emerging technologies. Expanding geographical footprints by targeting underpenetrated regions, while simultaneously adapting solutions to meet localized healthcare needs, stands as a robust strategy. Furthermore, capitalizing on digital transformations, such as incorporating artificial intelligence and machine learning algorithms into diagnostic workflows, will be essential in translating complex data into actionable insights. Emphasis should also be placed on developing customized solutions that cater to distinct patient segments, including adult, geriatric, and pediatric groups, ensuring a tailored approach. Strategic investments in research and maintaining an agile response to market needs will enable companies to not only sustain but also enhance their competitive advantage in this rapidly evolving sector.

Conclusion and Future Outlook

In conclusion, the non-invasive liver monitor market is on the cusp of a transformative era marked by rapid technological advancements and evolving clinical applications. This executive summary has elucidated how innovative diagnostic methods are reshaping clinical best practices by offering safer, more effective, and patient-centric alternatives to conventional procedures. The comprehensive segmentation insights, coupled with regional market dynamics and competitive landscape analyses, provide a clear roadmap for how different facets of the market interconnect. Moving forward, the integration of emerging technologies such as advanced imaging modalities and smart analytics will not only drive market growth but also enhance patient care significantly. The synthesis of strategic recommendations underscores the importance of cross-disciplinary collaborations and continuous innovation. As the market continues to mature, stakeholders are encouraged to adapt agile strategies that address both current challenges and future opportunities, ensuring that the progress achieved today paves the way for sustained success tomorrow.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing aging population globally necessitating advanced healthcare monitoring tools
    • 5.1.1.2. Growing patient acceptance of diagnostic procedures due to reduced discomfort and associated risks
    • 5.1.1.3. Government initiatives and funding support aimed at improving liver disease diagnosis and treatment
  • 5.1.2. Restraints
    • 5.1.2.1. High capital investment for purchasing and implementing advanced non-invasive liver monitoring systems
  • 5.1.3. Opportunities
    • 5.1.3.1. Expansion of telemedicine and remote patient monitoring enabled by digital health trends
    • 5.1.3.2. Collaborative partnerships between tech companies and healthcare providers promoting technology integration
  • 5.1.4. Challenges
    • 5.1.4.1. High production and supply chain issues ensuring quality control for non-invasive liver monitoring devices
• 5.2. Market Segmentation Analysis
  • 5.2.1. Test Types: Utilization of blood-based biomarker tests for their rapid turnaround time, cost-effectiveness
  • 5.2.2. Targeted Diseases: Growing of fatty liver disease due to obesity and alcohol consumption
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Non-Invasive Liver Monitor Market, by Test Types

• 6.1. Introduction
• 6.2. Blood-Based Biomarker Tests
• 6.3. Imaging-Based Tests

7. Non-Invasive Liver Monitor Market, by Technology

• 7.1. Introduction
• 7.2. Computed Tomography (CT)-Based Techniques
• 7.3. Magnetic Resonance Elastography (MRE)
• 7.4. Near-Infrared Spectroscopy (NIRS)
• 7.5. Serum Biomarker Panels & Scoring
• 7.6. Ultrasound Elastography

8. Non-Invasive Liver Monitor Market, by Application

• 8.1. Introduction
• 8.2. Disease Staging & Monitoring
• 8.3. Early Disease Diagnosis
• 8.4. Post-Surgery Monitoring

9. Non-Invasive Liver Monitor Market, by End-User

• 9.1. Introduction
• 9.2. Diagnostic Centers
• 9.3. Hospitals & Clinics
• 9.4. Research Institutions

10. Non-Invasive Liver Monitor Market, by Patient Type

• 10.1. Introduction
• 10.2. Adult
• 10.3. Geriatric
• 10.4. Pediatric

11. Non-Invasive Liver Monitor Market, by Targeted Diseases

• 11.1. Introduction
• 11.2. Cirrhosis
• 11.3. Fatty Liver Disease
• 11.4. Hepatitis
  • 11.4.1. Hepatitis B
  • 11.4.2. Hepatitis C
• 11.5. Liver Fibrosis

12. Americas Non-Invasive Liver Monitor Market

• 12.1. Introduction
• 12.2. Argentina
• 12.3. Brazil
• 12.4. Canada
• 12.5. Mexico
• 12.6. United States

13. Asia-Pacific Non-Invasive Liver Monitor Market

• 13.1. Introduction
• 13.2. Australia
• 13.3. China
• 13.4. India
• 13.5. Indonesia
• 13.6. Japan
• 13.7. Malaysia
• 13.8. Philippines
• 13.9. Singapore
• 13.10. South Korea
• 13.11. Taiwan
• 13.12. Thailand
• 13.13. Vietnam

14. Europe, Middle East & Africa Non-Invasive Liver Monitor Market

• 14.1. Introduction
• 14.2. Denmark
• 14.3. Egypt
• 14.4. Finland
• 14.5. France
• 14.6. Germany
• 14.7. Israel
• 14.8. Italy
• 14.9. Netherlands
• 14.10. Nigeria
• 14.11. Norway
• 14.12. Poland
• 14.13. Qatar
• 14.14. Russia
• 14.15. Saudi Arabia
• 14.16. South Africa
• 14.17. Spain
• 14.18. Sweden
• 14.19. Switzerland
• 14.20. Turkey
• 14.21. United Arab Emirates
• 14.22. United Kingdom

15. Competitive Landscape

• 15.1. Market Share Analysis, 2024
• 15.2. FPNV Positioning Matrix, 2024
• 15.3. Competitive Scenario Analysis
  • 15.3.1. Samaritan Family Health Center launch new non-invasive FibroScan service enhances liver health diagnostics
  • 15.3.2. Legacy MD launch non-invasive liver testing with Fibroscan
  • 15.3.3. Quibim launch AI-powered non-invasive liver monitor
• 15.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Alpinion Medical Systems USA Inc.
• 3. Bruker Corporation GmbH
• 4. Canon Medical Systems Corporation
• 5. Chison Medical Imaging Co., Ltd.
• 6. Clarius Mobile Health, Inc.
• 7. Echosens S.A.
• 8. Esaote S.p.A.
• 9. F. Hoffmann-La Roche AG
• 10. Fujifilm Holdings Corporation
• 11. GE HealthCare Technologies Inc.
• 12. Hologic, Inc.
• 13. iLiv Diagnostics Inc.
• 14. Konica Minolta, Inc.
• 15. Koninklijke Philips N.V.
• 16. Mindray Medical International Limited
• 17. Perspectum Diagnostics Ltd.
• 18. Quibim
• 19. Randox Laboratories Ltd.
• 20. Resonance Health Limited
• 21. Resoundant, Inc.
• 22. Samsung Medison Co., Ltd.
• 23. Siemens Healthcare Private Limited
• 24. Supersonic Imagine S.A.
• 25. Wuxi HISKY Medical Technologies Co., Ltd.